The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L- ribohexopyranosy l)oxy]- 1 1 , 12-dideoxy-6-O-methy 1-3-oxo- 12,11 -[oxycarbonyl[[4-[4-(3-pyridinyl)- 1 H- imidazol-l-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.